Body Composition Changes in Patients with Chronic Hepatitis C.
OBJECTIVE
We aimed to quantify global and regional body composition changes in chronic hepatitis C (CHC) patients, compare them to healthy controls and identify possible association between body composition changes and CHC. To our knowledge, this study is the first one comparing CHC patients to controls with regard to soft tissue body composition changes.


METHODS
We assessed 60 CHC patients and 60 healthy controls by Dual Energy X-Ray Absorptiometry. Soft tissue and bone body composition parameters were compared between the groups (using the Mann-Whitney test). These parameters were correlated (using Spearman's rank correlation coefficient - rho) with independent variables (age, gender, body mass index - BMI, cigarette smoking, time since CHC diagnosis, viral load, fibrosis grade, type of treatment, time of treatment) for the entire CHC group and also for subgroups according to gender.


RESULTS
Total fat mass, trunk fat mass and percent body fat were lower in CHC patients as compared to controls. Several risk factors were associated with the reduced fat mass: low BMI, cigarette smoking and peginterferon alpha 2a plus ribavirin treatment. Peginterferon alpha 2a and ribavirin treatment negatively correlated with lean body parameters, especially in CHC males group. Bone mineral density (BMD) was lower as compared to controls and was correlated with low BMI, cigarette smoking and peginterferon alpha 2a and ribavirin treatment.


CONCLUSIONS
Patients with CHC have an acquired type of lipodystrophy (particularly in the trunk region), and also a reduced BMD as compared with controls. A low BMI, cigarette smoking and peginterferon alpha 2a and ribavirin therapy were associated with a low fat mass and low BMD.
Carol Davila University of Medicine and Pharmacy Bucharest;Dr. I. Cantacuzino Clinical Hospital, Bucharest; Prof. Dr. Matei Balş National Institute for Infectious Diseases, Bucharest, Romania. katybarbu@yahoo.com.
Ecaterina Constanța
EC
Barbu
Carol Davila University of Medicine and Pharmacy Bucharest;Dr. I. Cantacuzino Clinical Hospital, Bucharest; Prof. Dr. Matei Balş National Institute for Infectious Diseases, Bucharest, Romania.
Cristina Emilia
CE
Chiţu-Tișu
Carol Davila University of Medicine and Pharmacy Bucharest; Prof. Dr. Matei Balş National Institute for Infectious Diseases, Bucharest, Romania.
Mihai
M
Lazăr
Carol Davila University of Medicine and Pharmacy Bucharest; Prof. Dr. Matei Balş National Institute for Infectious Diseases, Bucharest, Romania.
Cristina Mihaela
CM
Olariu
Carol Davila University of Medicine and Pharmacy Bucharest; University Emergency Hospital, Bucharest, Romania.
Dan
D
Olteanu
Carol Davila University of Medicine and Pharmacy Bucharest; Dr. I. Cantacuzino Clinical Hospital, Bucharest, Romania.
Mihai
M
Bojincă
Prof. Dr. Matei Balş National Institute for Infectious Diseases, Bucharest, Romania.
Adrian Octavian
AO
Abagiu
Carol Davila University of Medicine and Pharmacy; Prof. Dr. Matei Balş National Institute for Infectious Diseases, Bucharest, Romania.
Victoria
V
Aramă
Carol Davila University of Medicine and Pharmacy Bucharest, Romania.
Daniela Adriana
DA
Ion
Carol Davila University of Medicine and Pharmacy Bucharest, Romania.
Ioana Anca
IA
Bădărău
D015502:Absorptiometry, Photon; D050154:Adiposity / Q000187:drug effects; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D015992:Body Mass Index; D015519:Bone Density; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008060:Lipodystrophy / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D012307:Risk Factors; D012737:Sex Factors; D012907:Smoking / Q000009:adverse effects
D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a